PACB - Pacific Biosciences of California, Inc.
| Previous Close | 5.14 |
| Open | 5.17 |
| Bid | 5.06 x 3000 |
| Ask | 5.07 x 4000 |
| Day's Range | 5.05 - 5.17 |
| 52 Week Range | 4.37 - 7.70 |
| Volume | 806,555 |
| Avg. Volume | 1,568,507 |
| Market Cap | 783.457M |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings Date | Feb 10, 2020 - Feb 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 |
- Zacks
Here's Why You Should Hold on to Pacific Biosciences Stock
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
- Zacks
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
- Zacks
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
- Zacks
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Pacific Biosciences of California, Inc. Announces Third Quarter 2019 Financial Results
MENLO PARK, Calif., Nov. 07, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company’) today announced financial results for its third quarter ended.
- Zacks
Will Pacific Biosciences of California (PACB) Report Negative Q3 Earnings? What You Should Know
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Pacific Biosciences of California, Inc. (PACB)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
- GlobeNewswire
Highly Accurate SMRT Sequencing for Human Genetics to Be Showcased at ASHG 2019 Annual Meeting
MENLO PARK, Calif., Oct. 10, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and.
- Zacks
Here's Why You Should Retain Pacific Biosciences For Now
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
- Zacks
Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
Merger or Not, Pacific Biosciences Needs to Deliver
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
- Zacks
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
- Zacks
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
What Happens If Pacific Biosciences Isn't Acquired By Illumina?
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
- Motley Fool
Why J.C. Penney, QEP Resources, and Pacific Biosciences Slumped Today
Bad news on several different fronts held these stocks back.
- Motley Fool
Here's Why Pacific Biosciences Is Tumbling Today
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
- Motley Fool
Why Illumina Stock Jumped 20% in June
The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved.
- Zacks
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
- Insider Monkey
Here’s What Hedge Funds Think About Pacific Biosciences of California, Inc. (PACB)
We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Pacific Biosciences of California, Inc. (NASDAQ:PACB). Pacific […]
- Zacks
46 and You: Genetic Testing = Giant Growth Market
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
- TheStreet.com
Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal
In early November the companies said Illumina, the San Diego provider of DNA-sequencing technologies for research and clinical use, agreed to pay $8 a share for its Menlo Park, California, rival. The deal's enterprise value is $1.2 billion. Early in Wall Street trading, Pacific Biosciences shares fell 3% to $6.48.
- GlobeNewswire
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants
MENLO PARK, Calif., June 13, 2019 -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left.
- Zacks
Pacific Biosciences (PACB) Down 7.8% Since Last Earnings Report: Can It Rebound?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
